Merck Lowers Price of Isentress Drug for State AIDS Programs
This article is for subscribers only.
Merck & Co. reduced the price of AIDS drug Isentress for U.S. state programs that provide antiviral medicines to lower-income people who have limited or no insurance.
The price cut will happen on Jan. 1 and be effective through the end of 2013, the Whitehouse Station, New Jersey drugmaker said in a statement today. The company isn’t releasing the amount of the reduction, Pamela Eisele, a Merck spokeswoman, said in a telephone interview.